Gossamer Bio, Inc.
GOSSHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeGossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension. The $58.7M market capitalization puts GOSS squarely in micro-cap range for its industry. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Market Cap
$58.7M
Beta
2.21
P/E (TTM)
—
P/E (Fwd)
-0.62
EPS (TTM)
$-52.80
EPS (Fwd)
$-15.61
ROE
—
ROA
-62.4%
Cash
$57.0M
Total Debt
$40.1M
Free CF
-$29.8M
52W Change
-95.0%
Annual Financials
Cash vs Debt
Where GOSS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, GOSS finished 52.85% below its 150-day moving average ($17.88) and 83.16% below its 200-day moving average ($50.06). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GOSS overbought or oversold?
At the October 20, 2026 close, GOSS's RSI(14) was 17.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $57.0M in cash comfortably exceeding the $40.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$29.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet.
A beta of 2.21 means GOSS is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing GOSS.